GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHL

Abroad (travel likely)RecruitingPHASE1

Conditions

Non-hodgkin Lymphoma · Refractory Lymphoma · Chimeric Antigen Receptor T-cell

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Bing Xu, Xiamen, Fujian, China
Contact: Study coordinator (Bing Xu) · xubingzhangjian@126.com · +8618750918842

Study leads

Bing Xu
Principal Investigator
The First Aiffiliated hosptical of xiamen University

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)

Non-Hodgkin Lymphoma · Chronic Lymphocytic Leukemia · Acute Lymphocytic Leukemia

Abroad (travel likely)RecruitingPHASE1

Houston, United States · Houston, United States

A Study of Murine CD19 CAR-T Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancies

Acute Lymphoblastic Leukemia · Non-Hodgkin Lymphoma of Soft Tissue

Abroad (travel likely)RecruitingEARLY_PHASE1

Hangzhou, China

A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL

Hodgkin Lymphoma · B-Cell Lymphoma · Relapsed B-cell NHL

Abroad (travel likely)RecruitingPHASE2

Houston, United States

Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma

B-Cell Non-Hodgkin Lymphoma · Burkitt Lymphoma · Diffuse Large B-Cell Lymphoma, Not Otherwise Specified

Abroad (travel likely)RecruitingPHASE2

Seattle, United States